| Stereochemistry | ABSOLUTE |
| Molecular Formula | C4H5NO3S |
| Molecular Weight | 147.152 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H]1CSC(=O)N1
InChI
InChIKey=BMLMGCPTLHPWPY-REOHCLBHSA-N
InChI=1S/C4H5NO3S/c6-3(7)2-1-9-4(8)5-2/h2H,1H2,(H,5,8)(H,6,7)/t2-/m0/s1
Oxothiazolidinecarboxylic Acid (L-2-oxothiazolidine-4-carboxylic acid, OTC) was currently undergoing evaluation in a Phase II clinical trial. It is suggested that an ideal drug may be an antisense oligonucleotide that blocks the expression of glycolate oxidase, a key enzyme in hepatic oxalate synthesis.
CNS Activity
Approval Year
AUC
Doses
Sourcing
PubMed
Patents
Sample Use Guides
Oxothiazolidinecarboxylic Acid (L-2-oxothiazolidine-4-carboxylic acid, OTC), a prodrug of cysteine, was administered at a dose of 0.15 and 0.45 mmol/kg to healthy volunteers. The plasma concentration of OTC reached a peak between 45 and 60 min after p.o. administration.
Route of Administration:
Oral
Oxothiazolidinecarboxylic Acid (L-2-oxothiazolidine-4-carboxylic acid, OTC) was tested at concentrations of 5, 10, and 20 mM for its effect on acute
and chronic HIV-1 infection as measured by RT activity in
MDM isolated from adult peripheral blood and cord blood. Addition of OTC at a concentration
of 10 or 20 mM to chronically infected cord blood
MDM cultures also suppressed RT activity during the subsequent
course of infection.
SUBSTANCE RECORD
